{"id":750985,"date":"2023-04-25T16:06:25","date_gmt":"2023-04-25T20:06:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/"},"modified":"2023-04-25T16:06:25","modified_gmt":"2023-04-25T20:06:25","slug":"arcutis-to-report-first-quarter-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/","title":{"rendered":"Arcutis to Report First Quarter Financial Results"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WESTLAKE VILLAGE, Calif., April  25, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NfzDic7Augo3RQvc9nyQd9pNgDZIE3xX10iINOZegoLRQ6ZX8BtG0c_8bGzJBUTp9KBcpUyF9FnJuWXnU1Qvc4Ui3GpCHZVi7WltbO-cYVY=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Arcutis Biotherapeutics, Inc.<\/u><\/a>\u00a0(Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 4:30 p.m. ET on Tuesday, May 9, 2023, to report its first quarter financial results.<\/p>\n<p>The schedule for the press release and conference call\/webcast is as follows:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Q1 2023 Press Release:<\/strong>\u00a0Tuesday, May 9, 2023, after the close of the U.S. financial markets<\/li>\n<li>\n          <strong>Q1 2023 Earnings Call:<\/strong>\u00a0Tuesday, May 9, 2023, at 4:30 p.m. ET<\/li>\n<\/ul>\n<p>A live webcast of the call and the presentation material will be available on the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SwWPEmgFF_q04ttEORSsbhaVes-pOY7faBsuj4Pq-u_sF2mNwLFryRX1Nu300GMvmXI_aPWeMQywcwssBiKhRMymIOKx9siKR-HWvFYVCaurBehj6LyRCDJ9iKvs5I0Zst_ORVfIQvt4CuDKsvPflA==\" rel=\"nofollow noopener\" target=\"_blank\">Events<\/a>\u201d section of the Company\u2019s investor website. An archived replay of the webcast will also be available on the Arcutis investor website following the call.<\/p>\n<p>\n        <strong>About Arcutis<\/strong><br \/>\n        <br \/>Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio that harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis\u2019 dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, seborrheic dermatitis, and alopecia areata. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oHokWtlpCnRYKYfOZrPsZDhEOu-VD8Qkz4eZc6R9mB-pQwyJHkfS_eh9cyf99Lwhg_Sp6qxOw8P0wRqfOTpTNg==\" rel=\"nofollow noopener\" target=\"_blank\">www.arcutis.com<\/a>\u00a0or follow Arcutis on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pNLlFgJeK7oe6m-MWRv--U9DQ26F_LVWIOVfdVxMt8o1iMuGxOQY0vAbiahOiZ-Pri1z1b_x_Uhvfs9J_hntrIkpomy69B_jEwNKKyPHOpa_vQ5FzEguNmNW81pC_q7F\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LmTYMd1N14i0g89mU0MlYunxpnZJROsFSfXk9NvmSY4CrHlE-aOyXz3mg6yLHbkADhzeWZo8CNfTo0UmmZhyfYPOny2axk7MNlRs8uBvFx6Z4AniEA9SDMLGi6ZcEGFr\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a>, and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yQjdPSkOgCXCPGCFuD3ICSoV4Aq1quaf-bx_I4G_-L9-1Fq-AboaA6XSxQ-6qh5NZrho3zUty9SVOiMlP2ISmw==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking\u201d statements, including, among others, statements regarding its potential to address urgent needs and expectations with regard to the timing of data and regulatory events. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the \u201cRisk Factors\u201d section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 28, 2023, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em><br \/>\n            <u>Media<\/u><br \/>\n          <\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Amanda Sheldon, Head of Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nqQ8rljAQxXkOTGsDD86d9H8sbSZ3IudgqrnpTEHJM__0UXAXVkRf9m8TphWJpcGCtKMDsHW3wPXyaAqn68w7Szfyo1rucOZQHMeRiUPijc=\" rel=\"nofollow noopener\" target=\"_blank\">asheldon@arcutis.com<\/a><\/p>\n<p>\n        <strong><br \/>\n          <em><br \/>\n            <u>Investors<\/u><br \/>\n          <\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Eric McIntyre, Head of Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vh_kiMYcNDDAXGj4gUHvi1lesu1f7i71RBMecRFbE_lPu10dIcVGjTDvzW8_8twecvyXgO4Glc1cly8ZVPVv2OexVTi7-OyBfrDIW1DgXdo=\" rel=\"nofollow noopener\" target=\"_blank\">emcintyre@arcutis.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU1OCM1NTU0NTc5IzIxOTQwNTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YTQzODYzMDItMzk3NS00OTU1LWJkNDAtNDY1NWQ5NDU3MGU4LTEyMDU2MDM=\/tiny\/Arcutis-Biotherapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WESTLAKE VILLAGE, Calif., April 25, 2023 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc.\u00a0(Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 4:30 p.m. ET on Tuesday, May 9, 2023, to report its first quarter financial results. The schedule for the press release and conference call\/webcast is as follows: Q1 2023 Press Release:\u00a0Tuesday, May 9, 2023, after the close of the U.S. financial markets Q1 2023 Earnings Call:\u00a0Tuesday, May 9, 2023, at 4:30 p.m. ET A live webcast of the call and the presentation material will be available on the \u201cEvents\u201d section of the Company\u2019s investor website. An archived replay of the webcast will also &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Arcutis to Report First Quarter Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-750985","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arcutis to Report First Quarter Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcutis to Report First Quarter Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WESTLAKE VILLAGE, Calif., April 25, 2023 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc.\u00a0(Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 4:30 p.m. ET on Tuesday, May 9, 2023, to report its first quarter financial results. The schedule for the press release and conference call\/webcast is as follows: Q1 2023 Press Release:\u00a0Tuesday, May 9, 2023, after the close of the U.S. financial markets Q1 2023 Earnings Call:\u00a0Tuesday, May 9, 2023, at 4:30 p.m. ET A live webcast of the call and the presentation material will be available on the \u201cEvents\u201d section of the Company\u2019s investor website. An archived replay of the webcast will also &hellip; Continue reading &quot;Arcutis to Report First Quarter Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T20:06:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU1OCM1NTU0NTc5IzIxOTQwNTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-report-first-quarter-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-report-first-quarter-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arcutis to Report First Quarter Financial Results\",\"datePublished\":\"2023-04-25T20:06:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-report-first-quarter-financial-results\\\/\"},\"wordCount\":500,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-report-first-quarter-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDU1OCM1NTU0NTc5IzIxOTQwNTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-report-first-quarter-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-report-first-quarter-financial-results\\\/\",\"name\":\"Arcutis to Report First Quarter Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-report-first-quarter-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-report-first-quarter-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDU1OCM1NTU0NTc5IzIxOTQwNTA=\",\"datePublished\":\"2023-04-25T20:06:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-report-first-quarter-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-report-first-quarter-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-report-first-quarter-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDU1OCM1NTU0NTc5IzIxOTQwNTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDU1OCM1NTU0NTc5IzIxOTQwNTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcutis-to-report-first-quarter-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcutis to Report First Quarter Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arcutis to Report First Quarter Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Arcutis to Report First Quarter Financial Results - Market Newsdesk","og_description":"WESTLAKE VILLAGE, Calif., April 25, 2023 (GLOBE NEWSWIRE) &#8212; Arcutis Biotherapeutics, Inc.\u00a0(Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 4:30 p.m. ET on Tuesday, May 9, 2023, to report its first quarter financial results. The schedule for the press release and conference call\/webcast is as follows: Q1 2023 Press Release:\u00a0Tuesday, May 9, 2023, after the close of the U.S. financial markets Q1 2023 Earnings Call:\u00a0Tuesday, May 9, 2023, at 4:30 p.m. ET A live webcast of the call and the presentation material will be available on the \u201cEvents\u201d section of the Company\u2019s investor website. An archived replay of the webcast will also &hellip; Continue reading \"Arcutis to Report First Quarter Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-25T20:06:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU1OCM1NTU0NTc5IzIxOTQwNTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arcutis to Report First Quarter Financial Results","datePublished":"2023-04-25T20:06:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/"},"wordCount":500,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU1OCM1NTU0NTc5IzIxOTQwNTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/","name":"Arcutis to Report First Quarter Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU1OCM1NTU0NTc5IzIxOTQwNTA=","datePublished":"2023-04-25T20:06:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU1OCM1NTU0NTc5IzIxOTQwNTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDU1OCM1NTU0NTc5IzIxOTQwNTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcutis-to-report-first-quarter-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arcutis to Report First Quarter Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=750985"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750985\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=750985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=750985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=750985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}